Tuesday, August 12, 2008
Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole
Abstract Introduction To investigate the value of baseline serum levels of VEGF, bFGF, endostatin and their ratio as predictive factors of response to endocrine therapy in patients with metastatic breast cancer (MBC) and positive ER treated with letrozole after tamoxifen failure.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment